-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Glucocorticoid therapy is immune standard initial treatment for thrombocytopenia (ITP) patients
.
Although the initial response rate is 60-80%, only 30-50% of adults have a sustained response after stopping the drug
Glucocorticoid therapy is immune thrombocytopenia (ITP) initial methods of treating patients standard glucocorticoid therapy is immune standard initial treatment for thrombocytopenia (ITP) patients with immune
Recently, international guidelines have proposed a treatment algorithm that identifies TPO-RAs and splenectomy as second-line and third-line, respectively, confirming that splenectomy is only used as a second-line option in emergency situations
.
The international guidelines proposed a treatment algorithm that combined TPO-RAs with Splenectomy is determined as second-line and third-line respectively, confirming that splenectomy is only used as a second-line option in emergency situations
A foreign research team proposed a single-center observational retrospective study as a second-line treatment method
.
Since 2003, they have evaluated 48 adult patients with primary chronic ITP
The results suggest that the total effective rate of Eltrombopag is 94% , the CR rate is 76%, and the PR is 23%; only one patient did not respond and underwent splenectomy, followed by rituximab, romiplostim and Cyclosporine treatment obtains CR
.
One patient developed autoimmune pancytopenia about one month after starting TPO-RA.
The total effective rate of Eltrombopag is 94% .
In summary, this real-world single-center experiment confirmed the effectiveness and safety of Eltrombopag as a second-line treatment for patients with chronic ITP
Original source:
Gardellini A,Guidotti F,Feltri M,et al.
Leave a message here
